Liminatus Pharma, Inc. Class A Common Stock
Here’s whether Liminatus Pharma, Inc. Class A Common Stock (LIMN) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-4.47% over 10 days); weak 1-year return of -99.4%; 3-month momentum negative (-48.3%). Currently 99.6% off its 52-week high. Score: -6/7.
LIMN is trading below its 200-day MA ($0.81) — a key warning sign the longer-term trend is under pressure. An RSI of 34.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -99.4% compares to +22.9% for SPY (trailed the market by 122.3%). The current 99.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.